SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

TCRT

Alaunos Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Monitor for future IND-enabling study initiation and larger-scale manufacturing progress. Any upcoming financing will likely be dilutive given small market cap ($7M). Watch for replication of results in GLP or large-animal studies.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.32
T+0 close · Mar 2, 2026 · via day close
Latest settled
−26.20%
T+60 · $2.45
Vs SPY
−35.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $3.32entry
  2. T+1 · 9mo ago +0.90%α +1.82% · $3.35
  3. T+5 · 8mo ago +9.94%α +11.15% · $3.65
  4. T+20 · 8mo ago −15.06%α −7.12% · $2.82
  5. T+60 · 6mo ago −26.20%α −35.53% · $2.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mouse studies showing that its lead drug candidate, ALN1003, produced dose-dependent body weight loss, favorable body composition changes, reduced liver weight, and improved metabolic biomarkers. While the results are encouraging for a non-hormonal obesity treatment, the data are preliminary and subject to limitations, including potential confounding from reduced food and water intake in treated mice.

Key Facts

  • ALN1003 showed up to -12.9% mean body weight change vs control (p<0.0001) in DIO mice after 34 days
  • Liver weight reduced by up to 55% (high dose group, p<0.01) and liver enzymes (ALT, AST, ALP) improved
  • High-dose group had 197 mg/dL glucose vs 320 mg/dL in controls (p<0.0001), and lower total cholesterol
  • Drug was generally well tolerated, though mild hypolocomotion and dehydration in high-dose mice were observed
  • Company has $1.9M cash as of Sept 30, 2025, with runway into Q2 2026; additional financing planned

Financial Impact

No immediate financial impact; preclinical stage with no revenue or earnings. Cash runway extends to Q2 2026 with $1.9M, but dilutive financing likely needed.

cashdilutionR&D spend

Risk Factors

  • Preclinical mouse data may not translate to humans
  • Behavioral avoidance of medicated water may confound efficacy interpretation
  • Cash runway ends in Q2 2026; high risk of dilutive financing
  • Early-stage biotech with no clinical data or revenue

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247189

Track record

14 reports on TCRT

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.36% at T+60 after the Apr 15, 2026 report. 4 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago S-3 Bearish 6/10 Entry $1.63 Now $1.60 +1.84% settles Dec 14
  2. Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
  4. Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  5. Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  6. Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
  7. Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
  8. Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
  9. Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026